Shanghai Allist Pharmaceuticals Co. Ltd. Class ASSE: 688578

Announcement on Voluntary Disclosure of Obtaining of Approval Notice for the Drug Clinical Trial of Newly Approved Indication of Furmonertinib Mesylate Tablets

· Issued by Shanghai Allist Pharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining of Approval Notice for the Drug Clinical Trial of Newly Approved Indication of Furmonertinib Mesylate Tablets

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis

Earlier from Shanghai Allist Pharmaceuticals Co. Ltd. Class A

All Shanghai Allist Pharmaceuticals Co. Ltd. Class A news releases